JP2014534218A5 - - Google Patents

Download PDF

Info

Publication number
JP2014534218A5
JP2014534218A5 JP2014538927A JP2014538927A JP2014534218A5 JP 2014534218 A5 JP2014534218 A5 JP 2014534218A5 JP 2014538927 A JP2014538927 A JP 2014538927A JP 2014538927 A JP2014538927 A JP 2014538927A JP 2014534218 A5 JP2014534218 A5 JP 2014534218A5
Authority
JP
Japan
Prior art keywords
binding protein
tnf
fragment
seq
region
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2014538927A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014534218A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2012/061690 external-priority patent/WO2013063114A1/en
Publication of JP2014534218A publication Critical patent/JP2014534218A/ja
Publication of JP2014534218A5 publication Critical patent/JP2014534218A5/ja
Pending legal-status Critical Current

Links

JP2014538927A 2011-10-24 2012-10-24 Ｔｎｆを標的とする免疫結合剤 Pending JP2014534218A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161550587P 2011-10-24 2011-10-24
US61/550,587 2011-10-24
PCT/US2012/061690 WO2013063114A1 (en) 2011-10-24 2012-10-24 Immunobinders directed against tnf

Publications (2)

Publication Number Publication Date
JP2014534218A JP2014534218A (ja) 2014-12-18
JP2014534218A5 true JP2014534218A5 (enExample) 2015-12-17

Family

ID=47144149

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014538927A Pending JP2014534218A (ja) 2011-10-24 2012-10-24 Ｔｎｆを標的とする免疫結合剤

Country Status (26)

Country Link
US (2) US9803009B2 (enExample)
EP (1) EP2771362A1 (enExample)
JP (1) JP2014534218A (enExample)
KR (1) KR20140084253A (enExample)
CN (1) CN104093739A (enExample)
AR (1) AR088512A1 (enExample)
AU (1) AU2012328921B2 (enExample)
BR (1) BR112014009799A2 (enExample)
CA (1) CA2853357A1 (enExample)
CL (1) CL2014001054A1 (enExample)
CO (1) CO7020873A2 (enExample)
CR (1) CR20140225A (enExample)
DO (1) DOP2014000083A (enExample)
EC (1) ECSP14001249A (enExample)
HK (1) HK1200464A1 (enExample)
IL (1) IL232129A0 (enExample)
IN (1) IN2014CN03936A (enExample)
MX (1) MX2014004981A (enExample)
PE (1) PE20141545A1 (enExample)
PH (1) PH12014500866A1 (enExample)
RS (1) RS20140203A1 (enExample)
RU (1) RU2014120755A (enExample)
SG (1) SG11201401774VA (enExample)
TW (1) TW201326207A (enExample)
UY (1) UY34409A (enExample)
WO (1) WO2013063114A1 (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2771575A1 (en) 2009-08-29 2011-03-03 Abbott Laboratories Therapeutic dll4 binding proteins
WO2011109298A2 (en) 2010-03-02 2011-09-09 Abbott Laboratories Therapeutic dll4 binding proteins
KR20130100118A (ko) 2010-08-03 2013-09-09 아비에 인코포레이티드 이원 가변 도메인 면역글로불린 및 이의 용도
UY33679A (es) 2010-10-22 2012-03-30 Esbatech Anticuerpos estables y solubles
AR084210A1 (es) * 2010-12-08 2013-05-02 Abbott Lab PROTEINAS DE UNION AL TNF-a
UY34410A (es) 2011-10-24 2013-05-31 Abbvie Inc Inmunoligantes biespecificos dirigidos contra tnf
AU2012328921B2 (en) 2011-10-24 2017-05-11 Abbvie Inc. Immunobinders directed against TNF
AR088513A1 (es) 2011-10-24 2014-06-18 Abbvie Inc Inmunoenlazantes dirigidos contra esclerostina
PE20151179A1 (es) 2012-11-01 2015-09-12 Abbvie Inc Inmunoglobulinas de dominio variable dual anti-vegf/dll4 y usos de las mismas
EP2938637A2 (en) * 2012-12-28 2015-11-04 AbbVie Inc. Multivalent binding protein compositions
US9458244B2 (en) 2012-12-28 2016-10-04 Abbvie Inc. Single chain multivalent binding protein compositions and methods
AU2014337263B2 (en) 2013-10-16 2019-12-12 Outlook Therapeutics, Inc. Buffer formulations for enhanced antibody stability
US20160002326A1 (en) 2014-06-10 2016-01-07 Abbvie Inc. Compositions and methods for treating rheumatoid arthritis
US10093733B2 (en) 2014-12-11 2018-10-09 Abbvie Inc. LRP-8 binding dual variable domain immunoglobulin proteins
EP3247718B1 (en) 2015-01-21 2021-09-01 Outlook Therapeutics, Inc. Modulation of charge variants in a monoclonal antibody composition
TW201710286A (zh) 2015-06-15 2017-03-16 艾伯維有限公司 抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
AR104847A1 (es) 2015-06-17 2017-08-16 Lilly Co Eli Formulación de anticuerpo anti-cgrp
CN108350063A (zh) * 2015-09-14 2018-07-31 星系生物科技责任有限公司 针对血管生成因子的高度有效的单克隆抗体
CA3004830A1 (en) 2015-11-11 2017-05-18 Opi Vi- Ip Holdco Llc Composition and methods for anti-tnfr2 antibodies
GB201522394D0 (en) 2015-12-18 2016-02-03 Ucb Biopharma Sprl Antibodies
EP3411401A1 (en) 2016-02-03 2018-12-12 Oncobiologics, Inc. Buffer formulations for enhanced antibody stability
RS62040B1 (sr) 2016-06-02 2021-07-30 Abbvie Inc Agonist receptora glukokortikoida i njegovi imunokonjugati
WO2018085407A1 (en) * 2016-11-02 2018-05-11 Nanoproteagen Polymeric nanoparticles
EP3824906A1 (en) 2016-12-21 2021-05-26 Amgen Inc. Anti-tnf alpha antibody formulations
CN107903323B (zh) * 2017-11-15 2020-04-17 中国药科大学 抗hTNF-α全人源抗体及其用途
EP3658192B1 (en) 2017-12-01 2021-04-28 AbbVie Inc. Glucocorticoid receptor agonist and immunoconjugates thereof
WO2023205739A2 (en) * 2022-04-20 2023-10-26 Senti Biosciences, Inc. Antigen-binding domains and methods of use thereof

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4980286A (en) 1985-07-05 1990-12-25 Whitehead Institute For Biomedical Research In vivo introduction and expression of foreign genetic material in epithelial cells
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
DE3631229A1 (de) * 1986-09-13 1988-03-24 Basf Ag Monoklonale antikoerper gegen humanen tumornekrosefaktor (tnf) und deren verwendung
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
US5258498A (en) 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
FI903489A7 (fi) 1988-11-11 1990-07-10 Medical Res Council Yhden osan sisältävät ligandit, näitä ligandeja sisältävät reseptorit, menetelmiä niiden valmistamiseksi sekä ligandien ja reseptorien käytt ö
EP1690935A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
ES2139598T3 (es) 1990-07-10 2000-02-16 Medical Res Council Procedimientos para la produccion de miembros de parejas de union especifica.
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
DE69129154T2 (de) 1990-12-03 1998-08-20 Genentech, Inc., South San Francisco, Calif. Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
DE69233697T2 (de) 1991-03-01 2008-01-24 Dyax Corp., Cambridge Verfahren zur Entwicklung von bindenden Mikroproteinen
PT100379B (pt) 1991-04-10 1999-01-29 Scripps Research Inst Bibliotecas de receptores heterodimericos usando fagomideos
JPH07503124A (ja) 1991-06-14 1995-04-06 ゾーマ・コーポレーション 微生物によって生産される抗体断片とそれらの複合体
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
ES2301158T3 (es) 1992-07-24 2008-06-16 Amgen Fremont Inc. Produccion de anticuerpos xenogenicos.
DE69433279T2 (de) 1993-02-10 2004-07-15 Unilever N.V. Isolierungsverfahren verwendend immobilisierte proteine mit spezifischen bindungskapazitäten
US6091001A (en) 1995-03-29 2000-07-18 Abgenix, Inc. Production of antibodies using Cre-mediated site-specific recombination
US6130364A (en) 1995-03-29 2000-10-10 Abgenix, Inc. Production of antibodies using Cre-mediated site-specific recombination
AU705616B2 (en) 1995-04-21 1999-05-27 Cell Genesys, Inc. Generation of large genomic DNA deletions
CA2219361C (en) 1995-04-27 2012-02-28 Abgenix, Inc. Human antibodies derived from immunized xenomice
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
ATE239041T1 (de) * 1996-02-09 2003-05-15 Basf Ag Humane antikörper welche an humanen tnfalpha binden
US5714352A (en) 1996-03-20 1998-02-03 Xenotech Incorporated Directed switch-mediated DNA recombination
US6699658B1 (en) 1996-05-31 2004-03-02 Board Of Trustees Of The University Of Illinois Yeast cell surface display of proteins and uses thereof
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
EP1972194A1 (en) 1996-12-03 2008-09-24 Amgen Fremont Inc. Transgenic mammals having human ig loci including plural vh and vk regions and antibodies produced therefrom
IL131016A (en) 1997-01-21 2004-12-15 Gen Hospital Corp Selection of proteins using RNA-protein blends
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
KR20010034554A (ko) 1998-03-03 2001-04-25 레이몬드, 엠. 위티 치료제로서의 ｃｄ147 결합 분자
US20020029391A1 (en) 1998-04-15 2002-03-07 Claude Geoffrey Davis Epitope-driven human antibody production and gene expression profiling
JP2002522063A (ja) 1998-08-17 2002-07-23 アブジェニックス インコーポレイテッド 増加した血清半減期を有する改変された分子の生成
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
ES2706547T3 (es) 1998-12-23 2019-03-29 Pfizer Anticuerpos monoclonales humanos para CTLA-4
US7029872B2 (en) 2000-06-28 2006-04-18 Glycofi, Inc Methods for producing modified glycoproteins
US7449308B2 (en) 2000-06-28 2008-11-11 Glycofi, Inc. Combinatorial DNA library for producing modified N-glycans in lower eukaryotes
EP1345968A2 (en) 2000-12-28 2003-09-24 Altus Biologics Inc. Crystals of whole antibodies and fragments thereof and methods for making and using them
US20030186374A1 (en) 2001-10-01 2003-10-02 Hufton Simon E. Multi-chain eukaryotic display vectors and uses thereof
JP4754219B2 (ja) * 2002-12-02 2011-08-24 アムジエン・フレモント・インコーポレイテツド 腫瘍壊死因子を対象とする抗体、およびそれらの使用
WO2004063335A2 (en) 2003-01-08 2004-07-29 Applied Molecular Evolution TNF-α BINDING MOLECULES
CN1835974A (zh) 2003-06-16 2006-09-20 细胞技术研究与发展公司 对硬化素特异的抗体和用于增加骨矿化的方法
WO2006014477A1 (en) 2004-07-06 2006-02-09 Bioren, Inc. HIGH AFFINITY ANTI-TNF-α ANTIBODIES AND METHOD
US7592429B2 (en) 2005-05-03 2009-09-22 Ucb Sa Sclerostin-binding antibody
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
WO2008133722A2 (en) 2006-11-10 2008-11-06 Ucb Pharma S.A. Anti human sclerostin antibodies
US20100036091A1 (en) 2006-11-10 2010-02-11 Amgen Inc. Antibody-based diagnostics and therapeutics
EP2131860B1 (en) 2007-03-20 2013-12-18 Eli Lilly & Company Anti-sclerostin antibodies
AR068767A1 (es) 2007-10-12 2009-12-02 Novartis Ag Anticuerpos contra esclerostina, composiciones y metodos de uso de estos anticuerpos para tratar un trastorno patologico mediado por esclerostina
ES2579231T3 (es) 2008-01-15 2016-08-08 Abbvie Inc Vectores de expresión de mamíferos mejorados y usos de los mismos
EP2297209A4 (en) 2008-06-03 2012-08-01 Abbott Lab IMMUNOGLOBULINS WITH TWO VARIABLE DOMAINS AND USES THEREOF
NZ594514A (en) 2009-03-05 2013-06-28 Abbott Lab Interleukin-17 BINDING PROTEINS
UY32979A (es) 2009-10-28 2011-02-28 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
MX2012011629A (es) 2010-04-07 2013-03-05 Abbvie Inc Proteinas de union a tnf-alfa.
KR20130100118A (ko) 2010-08-03 2013-09-09 아비에 인코포레이티드 이원 가변 도메인 면역글로불린 및 이의 용도
AR084210A1 (es) * 2010-12-08 2013-05-02 Abbott Lab PROTEINAS DE UNION AL TNF-a
AU2012328921B2 (en) 2011-10-24 2017-05-11 Abbvie Inc. Immunobinders directed against TNF
UY34410A (es) 2011-10-24 2013-05-31 Abbvie Inc Inmunoligantes biespecificos dirigidos contra tnf
AR088513A1 (es) 2011-10-24 2014-06-18 Abbvie Inc Inmunoenlazantes dirigidos contra esclerostina
CA2904407A1 (en) 2013-03-15 2014-09-18 Abbvie Inc. Dual specific binding proteins directed against tnf.alpha.

Similar Documents

Publication Publication Date Title
RU2014120755A (ru) Иммуносвязующие агенты, направленные против tnf
JP2015502145A5 (enExample)
JP6866294B2 (ja) 抗ｐｄ−ｌ１抗体
JP2020534830A5 (enExample)
JP7778701B2 (ja) 抗ｓｔ２抗体及びその適用
JP2009005695A5 (enExample)
JP2017514461A5 (enExample)
JP2009517057A5 (enExample)
JP2013519364A5 (enExample)
JP2011527899A5 (enExample)
JP2025500971A5 (enExample)
JP2012501670A5 (enExample)
JP2022514179A5 (enExample)
RU2017134495A (ru) Антитела к альфа-рецептору собачьего интерлейкина-4
JP2011518546A5 (enExample)
CA2890455A1 (en) Blood-brain barrier (bbb) penetrating dual specific binding proteins
JP2012532851A5 (enExample)
RU2012103212A (ru) Tlr3 связывающие агенты
RU2011149334A (ru) Анти-il-17f антитела и способы их применения
JP2011207882A5 (enExample)
JP2017521054A5 (enExample)
JP2012514458A5 (enExample)
JP2016520595A5 (enExample)
JP2025503400A5 (enExample)
JP2023506465A5 (enExample)